Orchid Sells Genectables Business To Hospira

Hospira has moved another step up the value chain. The US-based firm has purchased the generic injectable pharmaceuticals business of India's Orchid Chemicals & Pharmaceuticals for US$400mn. Following the announcement of the deal, Orchid's share price dropped by more than 10%, while Hospira's rose. This suggests to BMI that Hospira has acquired an undervalued asset.

To read the full article, please choose one of the following options: